NASDAQ · Biotechnology · USD
PepGen Inc. (PEPG) Stock Analysis
PepGen Inc. (PEPG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
PEPG Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.89
- Previous Close
- $2.87
- Day's Range
- 2.72–2.99
- 52-Week Range
- 1.31–7.80
- Volume
- 1.17M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.01
Valuation
- Market Cap
- $188.14M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.01
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$89.66M
- Shares Outstanding
- 69.17M
- 1-Year Return
- −44.26%
Dividend and dates
- Earnings Date
- November 11, 2026estimated
- Avg Volume
- 907.74K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, PEPG closed at $2.72, −44.26% over 1 year.
PepGen Inc. (PEPG) has a market capitalization of $188.14M.
In fiscal 2025, PEPG reported revenue of $0.00.
PEPG Stock Return by Calendar Year
PepGen Inc. (PEPG) return since May 2022: what $10,000 became
- 1 year
- $10,000 $5,574
- −44.26%
- 3 years
- $10,000 $4,919
- −50.81%
- Since May 2022
- $10,000 $2,110
- −78.90%
If you had invested $10,000 in PepGen Inc. (PEPG) at the close on May 6, 2022, the earliest close on record here, it would have been worth $2,110 at the close on October 21, 2026: −78.90% in total, −29.45% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −58.22% |
| 2025 | +71.77% |
| 2024 | −44.26% |
| 2023 | −49.14% |
| 2022 (partial year) | +3.72% |
As of October 21, 2026.
PEPG Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$89.66M | — |
| 2024 | $0.00 | −$89.98M | — |
| 2023 | $0.00 | −$78.63M | — |
| 2022 | $0.00 | −$69.10M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$93.61M | −$89.66M | — |
| 2024 | $0.00 | — | −$97.74M | −$89.98M | — |
| 2023 | $0.00 | — | −$84.77M | −$78.63M | — |
| 2022 | $0.00 | — | −$68.30M | −$69.10M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $20 Price Target
BenzingaPepGen Q2 EPS $(0.26) Beats $(0.29) Estimate
BenzingaPepGen Receives Recommendation To Advance its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 In Participants With Myotonic Dystrophy Type 1 Into The Highest Dose Cohort
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B